Objective: To investigate the clinical effects and security of YiSuiShengXueGranule (YSSXG) on treating 156 patients with b b-thalassemia major. Methods: YSSXG was given orally to 156 patients with b b-thalassemia in GuangXi Autonomous Region (the high incidence area of b b-thalassemia in China) for 3 months as one therapeutic course, 3 times a day, 10 g each time (for children, the dose should be reduced properly according to their body weight and age), and no blood transfusion used during the course. Clinical symptoms and levels of hemoglobin (Hb), red blood cell (RBC), reticulocyte (Ret) and hemoglobin F (HbF) were observed before and after treatment, and side-effects were observed during the course. A 3-6 months follow up study was performed after withdrawal of YSSXG. And systemic gene analysis was conducted with PCR, SSCP-PCR, RT-PCR and DNA sequences analysis and mRNA differently expression technique, in order to study the molecular mechanism from the relationships between genetic mutation and clinical efficacy, gene expression and its regulation. Results: Levels of Hb, RBC, Ret and HbF obviously elevated, and clinical symptoms markedly meliorated in patients after treated with YSSXG from the 1st to 3rd month (all pϽ0.01). Dynamical observation showed that the improvement of symptoms kept accordance with the elevation of hemorrheological indexes. The treatment was effective in 145 patients and ineffective in 11, and the total effective rate was 92.9%, without any adverse reaction founded. Follow-up studies showed the therapeutic effect could sustain for 3 to 4 months after drug-withdrawal. The molecular mechanism study showed: YSSXG did not change the genetic mutation type, but could obviously increase g g/(b b؉g g) globin ratio, both g g-globin mRNA and GM-CSF mRNA expression were significantly enhanced so as to induce HbF synthesis increasing after treated with YSSXG. Conclusion: YSSXG had obviously effects in treating b b-thalassemia by unlocking g g-gene, increasing the g g-globin expression and enhancing HbF synthesis so as to compensate for the gene defect. This study has provided a new path for the treatment of b b-thalassemia with Traditional Chinese Medicine.
The thalassemias, the commonest monogenic diseases, are a family of inherited disorders of hemoglobin synthesis characterized by a reduced output of one or other of the globin chains of adult hemoglobin. The thalassemias are classified, according to the particular globin chain that is ineffectively produced, as the a, b, db and gdb thalassemias. The a and b thalassemias are by far the most important. It is a kind of hereditary hemolytic anemia, which distributed across the Mediterranean region, the Middle East, the Indian subcontinent, and throughout Southeast Asia in a line stretching from southern China down the Malaysian peninsula to the Indonesian islands. In China, the incident of the disease is particularly common in the southern provinces, especially higher in GuangXi Zhuang Autonomous Region, YunNan and GuiZhou Provinces (2-4.5%). The molecular pathogenesis is blamed to b-gene defect or inability g-gene incapability of initiation, and globin synthesis incompetence, which could result in early stage hematological disorder. And the curative therapies are currently available only to a small minority of patients.
The disease is harmful, and the prognosis of the severe type is especially serious. It could endanger children's health and hamper the constitutional improvement of people. Getting satisfactory approaches in its treatment remains one of the biggest troubles in clinical practice around the world.
Due to the difficulty in processing study, there has been no patent Traditional Chinese Medicine (TCM) preparation so far specifically for b-thalassemia treatment, either any deep study done in its therapeutic mechanism. Although some papers in TCM have touched upon the aspect, they only involved individual cases instead of affording any systematic study. Based on the TCM theory "kidney produce marrow, marrow produce blood, marrow and blood originate from kidney," the director of our stuff, Prof. Wu, composed YSSXG including 11 TCM kidney and blood supplementary herbs such as Fructus Corni, Radix Polygoni Multiflori, Radix Rehmanniae, Carapax Trionycis, Radix Codonopsis, Fructus Psoraleae and Radix Astragali, etc. After we got positive effects of enhancing Hb through animal experiments on exsanguine rats, we associated with the 303 Hospital of People's Liberate Army of China, which was the prevention and cure centre of b-thalassemia, and carried out longitudinal studies on b-thalassemia and achieved repetitive effects in our previous studies. 1, 2) The main theme of this paper is to describe new therapeutic options by using Traditional Chinese Medicine that might result in further improvements in the outlook for patients with these disorders. In the primary study we reported the clinical effects and security of YiSuiShengXueGranule (YSSXG) in treating 156 patients with bthalassemia major. General Materials From July 1989 to Jan. 2005, 156 assessable patients conforming to the case selecting criteria were chosen from the cities of Nanning, Baise and Hechi of Guangxi Zhuang Autonomous Region and their peripheral areas. They were 100 males and 56 females, aging from 2-31 with mean age of 11.08 years; 110 patients were of Zhuang nationality, 38 of Han nationality, 7 of Yao nationality and 1 of Buyi nationality; 150 were from Guangxi, 4 from Guangdong and 2 from Guizhou, and all from faraway mountainous regions. Gene types among 156 patients were: 63 were of severe type (18 accompanied with hemoglobin E) and 93 of moderate type (15 accompanied with hemoglobin E). Deferitrin therapy was never administered to them, blood transfusion was irregularly applied only to some patients of the severe type when in critical condition, and other anti-anemia drugs had never been applied in the past year before their enrolled in the study. All patients were willing to meet the requirements of the treatment.
Clinical Observation on
Clinical Symptoms Symptoms and signs manifested in patients were: anemia in different degrees starting from their childhood and liable to get colds, fever and cough, remarkable b-thalassemia face with pale yellow complexion.
Laboratory examination: Peripheral blood was collected for blood routine examine and hemoglobin electrophoresis. Hbs in the patients were 23-101 g/l; RBC 1.15-4.84ϫ 10 12 /l; reticulocyte (Ret) 0.02-0.38% and HbF 0.03-0.85%.
Eliminating criteria: Those who took frequently blood transfusion, or took other anti-anemia medicines, or had immune deficiency or other blood primary diseases and could not meet the requirement would be excluded.
Treatment YSSXG was produced by Guang'AnMen Preparation Factory which composed of 11 Chinese herbs, including Fructus Corni, Radix Polygoni Multiflori, Radix Rehmanniae, Carapax Trionycis, Radix Codonopsis, Fructus Psoraleae and Radix Astragali, etc. The herbs were extracted and made into granules, containing 2.368 g crude drugs in each gram of granule. It was given 3 times per day, 10 g each time by oral intake (the dose should be reduced properly for children) with 3 months as one therapeutic course. Observation lasted for one course, with no blood transfusion given in the treatment period. Patients who cannot meet the requirement would be excluded.
Evaluation of Hb, RBC, Ret and HbF Detecting of Hb, RBC, Ret and HbF were conducted every month. The time from withdrawal of YSSXG to the day when Hb or RBC got decreased or approached to the level of before treatment was determined as the effect maintaining time (taking month as the unit of measure). If the level of Hb or RBC during checking got decreased already to the level lower than that of before treatment, the time of last checking took place was taken as the end of effect maintaining time.
Evaluation of b b-Globin mRNA Transcription Level b-Globin mRNA transcription level was determined in 28 patients before and after the treatment. Pairs to pairs primer amplification methods were used to analyze a, b, g mRNA gene fragment, with three pairs of primers artificially composed in the following procedure: Extracting RNA→RT-PCR amplification→PAGE electrophoresis→radio-autographic examination→laser luminosity scanning. Then, the g/(bϩg) globin mRNA ratio was calculated. The blood samples before and after treatment of the patients were detected in pairs synchronously.
Detection of Globin Genetic Mutation Globin genetic mutation detection was carried out in 35 patients before and after treatment in the following procedure: Composing artificially the primer→sampling blood and separating WBC→ex-tracting total DNA→PCR amplifying→analyzing the amplifying fragment of genetic mutation point by PCR-SSCP to detect CD2 multiform→determining the genetic mutation type by integrated analysis with PCR-sDNA direct sequence detection.
Detection of GM-CSF mRNA Expression GM-CSF mRNA expression in peripheral blood of 28 patients was determined before and after treatment in pairs and tested synchronously in the following procedure: composing artificially the primer, and extracting RNA from the RBC isolating solution→reverse transcription reaction→RT-PCR amplification→ PAGE electrophoresis→radio-autographic examination→ laser luminosity scanning. The a-globin was used as inner standard and the changes of GM-CSF/a-globin ratio were regarded as the index for evaluating changes of GM-CSF mRNA transcription level.
Adverse Reaction Detection By detecting the blood routine, urine routine, liver function and kidney function every month in all the patients when they took YSSXG, we considered any abnormities about blood, urine, liver or kidney as adverse reactions.
Statistical Analysis The data were subjected to statistical analysis and results were expressed as meanϮS.D. (xϮs). Significance of differences was determined by use of a twotailed Student's t-test with software SPSS10. 0. A probability value of less than 0.05 was considered to be statistically significant.
RESULTS

Standard for Efficacy Evaluation
3) and referring to the criteria set up in The Fourth Hb Gene International Conference, 4) we took the treatment evaluated as effective when patient's Hb increased, no matter it increased alone or accompanied with elevation of Ret and/or HbF after treatment, which means the patient was responsive to the treatment. Increase of Ret was taken as referential index; whereas increase of HbF or Ret alone was of no importance in the efficacy evaluation.
Hematological Tests The changes of Hb, RBC, Ret and HbF of patients before and after treatment given in Table 1 showed that the indexes increased to some degree after treatment, and there were significant differences as compared with the data before treatment respectively. Hb and RBC of those 11 patients, who were not responsive to the therapy, got lowered after treatment due to no giving of blood transfusion, however, the clinical conditions were improved like those in the responsive cases, such as improving of spirit and appetite, insusceptibility to infectious diseases, and no adverse reaction. The improvement of the hematological indexes quite agrees with the clinical symptoms in all the patients.
Clinical Symptoms Clinical symptoms improved in those patients who were responsive to the treatment and proved to be always in high spirits and well states with improved appetite, thus rather insusceptible to infectious diseases. The treatment was effective in 36 of the 45 patients of severe type, 17 patients of severe type accompanied with hemoglobin E of total 18 cases were all responsive to the treatment. The treatment for the moderate type was effective for all 58 cases. And for the moderate type accompanied with hemoglobin E, 34 of all 35 cases were effective.
Effect on Globin mRNA Transcription Level After being treated for 3 months, of the 28 patients who had bglobin mRNA transcription determination performed, 23 showed a significantly increase in g/(bϩg) globin mRNA ratio, from 33.06Ϯ19.27 to 40.90Ϯ17.83, showing statistical significance in comparison between them (pϽ0.01), g/(bϩg) globin mRNA ratio in 2 patients remained unchanged and in 3 cases decreased slightly. The results indicated that YSSXG taking globin as its acting target, could stimulate g-globin gene transcription and expression, induce increase of HbF synthesis, and thus to compensate for the functional defect of globin gene in treating b-thalassemia.
Effect on GM-CSF mRNA Expression After being treated for 3 months, of the 28 patients receiving GM-CSF mRNA expression detection, the index significantly increased from 7.52Ϯ4.78% before treatment to 9.48Ϯ6.04% after treatment in 24 of them, showing significant statistical difference in the comparison of them (pϽ0.01), suggesting that YSSXG could remarkably stimulate GM-CSF mRNA expression in peripheral blood of b-thalassemia patients.
Relationship between Therapeutic Effects and b b-Globin Genetic Mutation Type (b b-GGMT) Systematic genetic mutation analysis before and after treatment was performed in 35 patients, among whom, 23 patients were of heterozygote b-GGMT, 4 of homozygote b-GGMT and 8 of heterogenic duplex heterozygote b-GGMT. The b-GGMT of patients before and after treatment was uniform, indicating that YSSXG did not change patients' b-GGMT. The effect of YSSXG on different genetic mutations was significantly different.
Analysis on the relationship between therapeutic effect and b-GGMT in patients showed that the therapeutic effects of the treatment were different on patients with different b-GGMT, better on patients of heterogenic duplex heterozygote 2086 Vol. 30, No. 11 Table 3 . Relationships between Genetic Mutation Type and Therapeutic Effects Genetic mutation type Cases Therapeutic effects Effective ratio
types than on those of heterozygote and homozygote type. Adverse Reaction By detecting the blood routine, urine routine, liver function and kidney function, no adverse reaction was shown in all the patients when they took YSSXG.
DISCUSSION
There has been found no special effective measures for treatment of b-thalassemia so far just like for most hereditary diseases. Blood transfusion is the main measures, and a few patients have been reported to be cured by chemical preparations such as 5-azacytidine, cytarabine and hydroxyurea. 5) Myleran has been used by some Chinese doctors to treat bthalassemia, although it can induce increase of Hb and HbF, but its high adverse reactions impede its wide use in clinical practice. Splenectomy and splenic embolism for severe type b-thalassemia are just a palliative treatment. Use of bone marrow transplantation is limited owing to the difficulty in attaining source and matching type of marrow. Gene import shows a very good prospect, but it can not be widely used in clinical practice due to the low autoploidy recombination. So, up to now, to find a clinical effective treatment is still a hard task facing doctors all over the world.
According to the TCM theory that "kidney producing marrow", YSSXG, a composite recipe for nourishing kidney and supplementing marrow was manufactured by the authors for treatment of b-thalassemia, which has been used in Guangxi Autonomous Region, where the incidence of the disease is high. And we are glad to say that good efficacy has been obtained. By the clinical practice in more than ten years, it is proved that the drug is definitely effective, and the effect is repeatable. Myleran has been reported to be used in treating 13 patients of b-thalassemia, and proved to be effective in 8 patients and ineffective in 5, but it showed such adverse reactions as decrease of platelet and leukocyte, and concomitant fever, even causing the therapy to be discontinued in 3 patients. 6, 7) While YSSXG treatment showed, in this study, its good prospect and superiority: definite therapeutic effect and no adverse reaction in treating b-thalassemia, which not only verifies the objectivity of TCM theory on kidney producing marrow , but also initiates a new way for treatment of b-thalassemia by TCM.
Based on the clinical research, the authors had systematic analysis of genetic type and observation of globin mRNA transcription level carried out. Results showed that YSSXG does not change genetic mutation type, yet shows certain effect on patients with any type of genetic mutation. However, the effect on patients with heterozygote genetic mutation is better than on those with homozygote mutation and heterogenic duplex heterozygote genetic mutation. The peripheral blood g-globin mRNA transcription level and g/(bϩg) globin mRNA ratio got evidently elevated after 3 months of YSSXG treatment, indicating that YSSXG can enhance gglobin mRNA expression. Studies also showed that YSSXG could significantly increase GM-CSF mRNA expression level.
YSSXG is an effective Chinese herbal preparation for treatment of b-thalassemia, which is characterized significantly by increasing the life quality of patients, improving their clinical symptoms and enhancing the integrative effect of treatment. The mechanism for its effect is possibly by opening g-gene, promoting g-globin mRNA expression, inducing increase of HbF synthesis, so as to compensate for the functional deficiency of b-gene. This study has provided a theoretical and practical base for the treatment of b-thalassemia by TCM.
